You need IP intelligence to meet corporate objectives related to your business function. IP Street is driving the innovation economy and managing IP assets with know-how and confidence. IP Street.com takes a patent search to a whole new level by helping you better understand patent analytics, patent duration, patent value, patent infringement and the steps needed to patent an idea or patent an invention.

Patents have a maximum life of 20 years and, therefore, a 20-year potential monopoly. Patents that are just beginning their life and which have longer to run on the their potential monopoly position understandably will have more value. It is rare that a patent nearing the end of its term will cause a great threat to its competitors. It is almost certain that they will have devised technologies or products of their own by then that will not interfere with the patent owners monopoly position. In addition, one has to take into consideration the potential business life of a patent, i.e., the duration, which a patent is likely to be economically useful, if other subsequent patents are providing better alternatives to it.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

You need IP intelligence to meet corporate objectives related to your business function. If you are a HR director, you can utilize TalentScout™ to identify the inventors that are essential to corporate success. If you are an IP portfolio manager, you can utilize our tools to identify the IP landscape. If you are a licensing executive, you can utilize our tools to identify potential inbound and outbound relationships. IP Street will assist you in better understanding patent duration and patent analytics.

Traditionally, IP counselors are buffered from the senior-executive decision-making process. Although patent attorneys represent an elite group that have a scientific background, this technical background many times prevents you from being a part of top-level strategic decisions. With your subject-matter expertise, and our ability to convert the complexities of the patent space into actionable business intelligence, you can earn a seat in the executive board room. Connie from Lee & Hayes says, " As an IP attorney, I specialize in life sciences technologies and need tools that go beyond a good search. I use IP Street's suite of tools because the analysis provides great business insights in a fraction of the time it used to take, allowing me to be more responsive to my clients with better information. As a result, I am able to play a more integral role in my clients' business. " It is about time you can communicate actionable business intelligence from patent documents. Executives are starting to recognize the importance of Intellectual Assets and their management, but they need more. An you can provide it for them.